Tag: oral immunotherapy (OIT)

AAAAI Logo + Palforzia

AAAAI Addresses What Patients and Their Families Need to Know About...

As the FDA moves closer to approving the first food allergy treatment, the AAAAI seeks to help patients and their families understand the realities surrounding OIT.
Peanuts

Study: Few People with Peanut Allergy Tolerate Peanut after Stopping OIT

Continuing with a modest dose confers more protection, NIH-funded study finds.
Paliforzia (AR101)

FAQ for Palforzia, About to Become the First FDA Approved Therapy...

What it is, what it treats, who it is for, how it is used, et al.
Patient Undergoing SLIT

New Peanut Allergy Treatment Passes Phase 2 Trial, Shows Effectiveness and...

UNC School of Medicine researchers show that tiny under-the-tongue doses of peanut protein can offer safe and substantial protection against peanut allergy.
Eggs

Aimmune Enrolls First Patient in Phase 2 Trial of AR201 for...

AR201 is the second development program that Aimmune is advancing to phase 2 using its Characterized Oral Desensitization ImmunoTherapy (CODIT™) platform.
AR101

FDA to Hold Open Advisory Meeting on AR101 Peanut Allergy OIT...

CBER will provide a live webcast of the committee meeting free of charge.
Omalizumab + OIT

Clinical Trial to Evaluate Experimental Treatment in People Allergic to Multiple...

NIH and partners to assess whether Omalizumab can reduce allergic reactions.
FARE Reponse to ICER Report

Fare Responds to Final ICER Review of Breakthrough Peanut Allergy Therapies

FARE expresses its deep concerns with the final evidence report on two breakthrough peanut allergy therapies issued Wednesday by ICER.
AAFA Reponse to ICER Report

Asthma and Allergy Foundation of America Responds to Premature ICER Review...

The AAFA addresses concerns regarding the Final Evidence Report released by the ICER.
Aimmune Reponse to ICER Report

Aimmune Statement on Institute for Clinical and Economic Review (ICER) Final...

Exclusion of long-term desensitization and patient quality-of-life data by ICER fails to recognize the full value AR101 immunotherapy can deliver to the peanut allergy community.

Connect with Us

40,035FansLike
960FollowersFollow
2,765FollowersFollow
5,603FollowersFollow
42SubscribersSubscribe